Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Biopharm Drug Dispos. 2011 Sep 22;32(8):471–481. doi: 10.1002/bdd.770

Figure 1.

Figure 1

Pharmacokinetic models for denosumab (A) and ibandronate (B). For (A), drug administered subcutaneously is absorbed (ka) into the plasma compartment (Cp, Vc) and undergoes linear (kel) and nonlinear (Vmax, Km) elimination. Model shown in (B) is a linear 4-compartment model with a bone-specific site originally described by Pillai et al. [8].